GERMANTOWN, MARYLAND / ACCESS Newswire / March 4, 2025 / uBriGene Biosciences (uBriGene), a leading cell and gene therapy CDMO, is pleased to announce the submission of its Drug Master File (DMF) for ...
Faster Clinical Translation and Commercialization of Therapies Derived From iPSC Technology GERMANTOWN, MARYLAND / ACCESS Newswire / March 4, 2025 / uBriGene Biosciences (uBriGene), a leading cell and ...
New L7™ PBMC Reprogramming Bundle for the Simple, Rapid and Reliable Generation of hiPSCs from PBMCs
The new L7™ PBMC Reprogramming Bundle slots seamlessly into the existing L7™ workflow to enable researchers to reprogram peripheral blood mononuclear cells (PBMCs) for use in downstream experiments.
GERMANTOWN, MD / ACCESS Newswire / September 17, 2025 / uBriGene Biosciences, a leader in CGT CDMO and iPSC manufacturing technology development, today announced the launch of its 2nd-Generation iPSC ...
uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells
RNA-LNP Based, Non-Viral Delivery - RNA-LNP delivery avoids genome integration risks, leaving no genetic footprint. Optimized for PBMCs - The only non-viral kit proven effective for PBMC reprogramming ...
An international team led by researchers at Lund University in Sweden has identified the molecular tools needed to reprogram ordinary cells into specialised immune cells. The discovery, published in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results